Select Language:
Shares of Berry Genomics rose after the country’s regulatory authorities approved its subsidiary’s third-generation gene sequencer, marking the first device of its kind authorized for clinical use domestically. The company’s stock closed approximately 6.1 percent higher at 13.89 yuan ($1.95) per share, reaching the daily trading limit during the session. The broader market in the region experienced a modest increase of 0.2 percent.
The new sequencing device leverages single-molecule real-time sequencing technology. It can support genetic disease diagnosis and evaluate disease susceptibility by sequencing human DNA samples within clinical settings. The company highlighted that it has independently developed testing reagents compatible with this advanced sequencing technology and offers comprehensive services from data collection to report analysis.
The widespread use of third-generation sequencing technology is expected to accelerate major public health initiatives, such as birth defect prevention and control, both locally and globally. The company aims to make the technology more accessible by optimizing artificial intelligence algorithms and enhancing local deployment options, enabling more families to receive precise, quick, and cost-effective testing services.
Compared to previous generations, this latest gene sequencer provides more accurate interpretation of specific genetic sequences and significantly reduces testing time by delivering end-to-end localized services—from sample collection to data analysis and report generation.
ChatGPT
Perplexity
Gemini AI
Grok AI
